Evidence map›Paper›PMID 42711892›Full record

ArticleRadiology and oncology2026

Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer.

Vladimir Stojsic, Bojan Zaric, Petar Simurdic, Tomi Kovacevic, Darijo Bokan, Jelena Djekic Malbasa, Tatjana Sarcev, Goran Stojanovic, Daliborka Bursac, Borislava Nikolin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vladimir Stojsic1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Bojan Zaric1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Petar Simurdic1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Tomi Kovacevic1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Darijo Bokan1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Jelena Djekic Malbasa1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Tatjana Sarcev1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Goran Stojanovic2Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Daliborka Bursac1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Borislava Nikolin1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPembrolizumab monotherapy is standard of care in first line treatment of patients with stage IV lung cancer and programmed death ligand 1 (PD-L1) expression ≥ 50%. Whether the higher levels of PD-L1 expression predict higher benefit from the treatment with pembrolizumab is still debatable. PATIENTS AND

methodsThis trial analyzed clinical and pathological characteristics, overall response rate (ORR), and survival outcomes in patients with non-small cell lung cancer (NSCLC) and PD-L1 expression of ≥ 50% who received front line treatment with pembrolizumab in real-world setting. The aim was to evaluate does the level of expression influence survival endpoints.

resultsFifty-one consecutive patients were evaluated in this study. The median PFS for patients in this study was 12.0 months (95% CI, 7.7-16.2 months), and the median OS was 21.0 months (95% CI, 9.6-32.3 months). Based on PD-L1 status patients were divided into two groups. First one with PD-L1 expression of 50%-79%, and the second with expression over 80%. Gender distribution between the two groups (p = 0.029) and difference in stage of the disease (p = 0.039) were statistically significant. There was no significant difference in progression free survival (p = 0.548) and overall survival (p = 0.153) between two groups.

conclusionsThis trial did not confirm relation between higher expression of PD-L1 and better survival outcomes. However, the pitfall of the trial was relatively small number of patients, so with the expansion of this real-world data (RWD) dataset future results might differ.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansImmunotherapyMaleMiddle AgedNeoplasm StagingTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanpembrolizumabimmunotherapylung cancerNSCLCPD-L1pembrolizumab

Identifiers

PMID42711892
PMCPMC13554301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.